Mondobiotech Holding AG Company presentation

mondoBIOTECH’s IP Strategy: Two Independent Exclusivity Rights
• Our Medicinal Product Candidates (MPCs) are already known peptides, whose properties and mechanisms of actions are described in
millions of publications
• Many of our MPCs have already been on the market for a different indication or were tested in humans for a different indication
• Each of our MPCs is a product platform which can be re-directed for a variety of new indications, in rare diseases and potentially in nonrare
diseases
PATENT INVENTION
Invention object of the patent is:
NOVEL
Invention object of the patent is:
NON-OBVIOUS
Invention object of the patent
feasible for:
INDUSTRIAL APPLICATION
Combination or
First Medical Use of
the peptide or of a
combination not
yet disclosed in
literature
Combination or
First Medical
Use of the
peptide or the
combination is
not obvious for
the experts in
the field
✔
ok
1 st 2 nd
Second Medical Use
for one or more
diseases of the
peptide or of a
combination not yet
disclosed in literature
Second Medical
Use for one or
more disease of
the peptide or
of a
combination is
not obvious for
the experts in
the field
✔
ok
ORPHAN DRUG INVENTION
PREVALENCE
MEDICAL
NEED
ORPHAN DRUG
DESIGNATION
1 st 2 nd
US: not more than 200’000
Patients
and/or
EU: not more than 5 patients
in 10’000 people
The disease has a wide prevalence,
but it is not attractive in terms of
economic return
• No diagnostic tool, treatment and/or preventive solution exists
• The Sponsor demonstrate that the MPC shows substantial
benefits over approved treatments
✔ ok
✔ ok
33